Indicaton

GI disorders

Debio 025 (alisporivir) is the first in a new class of drugs called cyclophilin inhibitors, with a potential in a wide range of therapeutic indications. Alisporivir was first thoroughly investigated for its antiviral properties in hepatitis C and HIV patients and consequently benefits from a large safety and efficacy database. Today, our development efforts are focused on non-viral diseases where cylophilins play a key role in regulating cell death pathways and we strive to generate compelling evidence supporting further clinical investigations in patients with high unmet medical needs.

Therapeutic indications
Type of product
Table
  • Phase
    Discovery
  • Partnering status
    Not partnered